ISSN 2327-2236
Vol. 3, Issue 2, 2016November 16, 2015 EDT
Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
Articles in Vol. 3, Issue 2, 2016
Vol. 3, Issue 2, 2016
- Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of TherapyGabriel TremblayUnnati MajethiaIlias KontoudisJesús De Rosendo
- Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort StudyTao GuNeel ShahGaurav DeshpandeDerek H. TangDebra F. EisenbergDavid J. Harrison
- A Characterisation and Profiling of District Health Indicators in Zimbabwe: An Application of Principal Component Analysis in a Data Limited SettingShepherd ShamuSimbarashe RusakanikoCharles Hongoro
- How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA GuidelinesLindsay GovanOlivia WuRobert LindsayAndrew Briggs
- Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell TransplantsSantiago GrauCarlos SolanoCarol García-VidalIsidro JarqueJon A. BarruetaCarmen PeralIrene RodríguezDarío Rubio-RodríguezCarlos Rubio-Terrés
- Montelukast Use and Patterns of Ambulatory Care among Asian versus Non-Asian Adult Patients with Asthma and/or Allergic Rhinitis in the United StatesJoseph VaseyShalini BaggaHuan HuangTongsheng WangDavid Thompson
- Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive ChemotherapyNovember McGarveyHairong Xu
1.
McGarvey N, Xu H. Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy. JHEOR. 2015;3(2):214-223. doi:10.36469/9836
